EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Mechanistic and translational perspectives on m6A RNA modification in bladder cancer

Xi Huang, Jieling He, Zijian Zhao, Yuchen Liu, Congcong Cao, Ruilin Yang

Discover Oncology · 02.11.2026

DOI: 10.1007/s12672-026-06194-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Discover Oncology, online erschienen am 02.11.2026. Verfasst von Xi Huang und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: General Guidance Project of Guangzhou Health Science and Technology, Guangzhou., Key Program of Medical and Health Project of Panyu Science and Technology Funds, Panyu, Guangzhou..

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

N6-methyladenosine (m6A) is a reversible and context-dependent RNA modification that links transcript processing to bladder cancer growth, immune escape, treatment response, and tumor-cell plasticity. This review asks three questions: which m6A mechanisms have been experimentally resolved in bladder cancer; how CRISPR systems can establish causal relationships at regulator, transcript, and nucleotide levels; and which targets are sufficiently supported for translational development. We report the experimental settings represented for each axis and assess mechanistic resolution separately; cross-cancer observations are retained only as hypotheses for bladder cancer. Bladder-cancer evidence identifies oncogenic METTL3-centered axes involving AFF4-NF-kB-MYC, ITGA6, pri-miR-221/222-PTEN, RPN2, and PD-L1; an FTO-MALAT1-miR-384-MAL2 axis; YTHDF2-dependent degradation of DDX58/RIG-I; WTAP-NRF2 regulation; and IGF2BP3-mediated stabilization of HMGB1. Reader-resolved axes include METTL3-ITGA6-YTHDF1/3, WTAP-NRF2-YTHDF1, FTO-MALAT1-YTHDF2, YTHDF2-DDX58, IGF2BP3-HSP90AB1, and IGF2BP3-CDK6; METTL3-RPN2-YTHDF1 and METTL3-PD-L1-IGF2BP1 remain reader-implicated because direct reader-target binding was not demonstrated, and RPN2 additionally lacks experimental target-specific m6A mapping. IGF2BP3-HMGB1, YTHDC1-HECW1 and IGF2BP3-PPARγ also remain reader-implicated, with m6A dependence unestablished for HMGB1 and HECW1. No axis has achieved site-resolved validation with site-mutant phenotypic rescue in an immune-competent orthotopic model. METTL14 findings remain directionally inconsistent. Cas9/Cas12a DNA editing, active Cas13 RNA knockdown, and inactive RNA-targeting Cas platforms carrying m6A effectors are treated as distinct technologies. Two bladder-cancer proof-of-concept studies used guide-directed m6A editing: RCas9-METTL3 targeted CDCP1, and a multisite dCasRx-METTL3/ALKBH5 platform targeted ITGA6. These experiments support causal research applications but do not constitute an established therapy. We propose a controlled workflow integrating m6A mapping, genetic perturbation, site-mutant rescue, reader identification, organoids, in vivo models, and therapy-response assays. Detection, biomarker development, pharmacology, delivery, and safety are evaluated with emphasis on analytical validity and the absence of clinical validation for m6A-directed treatment in bladder cancer.

Förderung

  • General Guidance Project of Guangzhou Health Science and Technology, Guangzhou.
  • Key Program of Medical and Health Project of Panyu Science and Technology Funds, Panyu, Guangzhou.

Zitieren

APA

Huang, X., He, J., Zhao, Z., Liu, Y., Cao, C., & Yang, R. (2026). Mechanistic and translational perspectives on m6A RNA modification in bladder cancer. Discover Oncology. https://doi.org/10.1007/s12672-026-06194-4

Vancouver

Huang X, He J, Zhao Z, Liu Y, Cao C, Yang R. Mechanistic and translational perspectives on m6A RNA modification in bladder cancer. Discover Oncology. 2026. doi:10.1007/s12672-026-06194-4

BibTeX
@article{Huang2026,
  author = {Huang, Xi and He, Jieling and Zhao, Zijian and Liu, Yuchen and Cao, Congcong and Yang, Ruilin},
  title = {Mechanistic and translational perspectives on m6A RNA modification in bladder cancer},
  journal = {Discover Oncology},
  year = {2026},
  doi = {10.1007/s12672-026-06194-4}
}
Kostenlos starten →